VKTX logo

VKTX
Viking Therapeutics Inc

38,148
Mkt Cap
$3.74B
Volume
3.52M
52W High
$43.15
52W Low
$18.92
PE Ratio
-10.16
VKTX Fundamentals
Price
$32.33
Prev Close
$33.92
Open
$33.62
50D MA
$32.02
Beta
1.53
Avg. Volume
3.22M
EPS (Annual)
-$3.19
P/B
5.81
Rev/Employee
$0.00
$3,258.03
Loading...
Loading...
News
all
press releases
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the latest study.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·3d ago
News Placeholder
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
Zacks·4d ago
News Placeholder
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
Key PointsEli Lilly is the leader in the U.S. weight loss drug market, with a 60% share...
Nasdaq News: Markets·4d ago
News Placeholder
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) reached $36.01 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.
Zacks·5d ago
News Placeholder
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
Key PointsACT Capital acquired 206,100 shares of Viking Therapeutics in the fourth quarter...
Nasdaq News: Markets·5d ago
News Placeholder
Viking Therapeutics, Inc. $VKTX Stock Holdings Cut by Braidwell LP
Braidwell LP lessened its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 47.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional...
MarketBeat·7d ago
News Placeholder
Baker BROS. Advisors LP Acquires New Shares in Viking Therapeutics, Inc. $VKTX
Baker BROS. Advisors LP bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the third quarter, according to the company in its most recent filing with the Securities...
MarketBeat·7d ago
News Placeholder
Viking Therapeutics, Inc. $VKTX Shares Acquired by Quinn Opportunity Partners LLC
Quinn Opportunity Partners LLC increased its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 50.7% in the 3rd quarter, according to the company in its most recent...
MarketBeat·8d ago
News Placeholder
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·9d ago
<
1
2
...
>

Latest VKTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.